Familial combined hyperlipidemia in children: Clinical expression, metabolic defects, and management*
References (59)
- et al.
Prevalence and expression of familial combined hyperlipidemia in childhood
J Pediatr
(1990) - et al.
Family study of serum lipids and lipoproteins in coronary heart disease
Lancet
(1973) - et al.
Inheritance of combined hyperlipoproteinemia: evidence for a new lipoprotein phenotype
Am J Med
(1973) - et al.
Familial aggregation and early expression of hyperapobetalipoproteinemia
Am J Cardiol
(1985) - et al.
Genetic evidence from 7 families that the apolipoprotein B gene is not involved in familial combined hyperlipidemia
Atherosclerosis
(1990) - et al.
Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein B kinetics in man: normolipidemic subjects, familial hypertriglyceridemia and familial combined hyperlipidemia
Metabolism
(1981) - et al.
Measurement of apolipoprotein B synthesis in perfused rat liver using stable isotopes: [15N]hippurate as a measure of the intracellular [15N]glycine precursor enrichment
J Lipid Res
(1989) - et al.
Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoportien receptor-related protein
J Biol Chem
(1990) - et al.
Apolipoprotein C-I modulates the interaction of apolipoprotein E with β- migrating very low density lipoproteins (β-VLDL) and inhibits binding of β-VLDL to low density lipoprotein receptor-related protein
J Biol Chem
(1990) - et al.
Kinetics of chylomicron remnant clearance in normal and hyperlipoproteinemic subjects
J Lipid Res
(1987)
Long-term follow-up of children with familial hypercholesterolemia treated with cholestyramine
Lancet
Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia
J Lipid Res
Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production
J Lipid Res
Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins
Metabolism
Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis: the Bogalusa Heart Study
N Engl J Med
Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking
JAMA
Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction
J Clin Invest
Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia
J Clin Invest
Familial Combined Hyperlipidemia Workshop
Arteriosclerosis
Biochemical, clinical, genetic and metabolic studies of hyperapo-β-lipoproteinaemia
J Inher Metab Dis
Association of coronary atherosclerosis with hyperapobetalipoproteinemia (increased protein but normal cholesterol levels in human low density [beta] lipoproteins)
Proc Natl Acad Sci USA
DNA polymorphisms in and around the apo-AI-CIII gene and genetic hyperlipidemias
Am J Hum Genet
Familial combined hyperlipidaemia linked to the apolipoprotein AI-CIII-AIV gene cluster on chromosome 11q23–q24
Nature
Evidence against linkage of familial combined hyperlipidemia to the AI-CIII-AIV gene complex
Circulation
Major locus inheritance of apolipoprotein B in Utah pedigrees
Genet Epidemiol
Linkage and segregation analyses of apolipoproteins A-1 and B, and lipoprotein cholesterol levels in a large pedigree with excess coronary heart disease
Genet Epidemiol
Sources of inter-individual variation in the quantitative levels of apolipoprotein B in pedigrees ascertained through a lipid clinic
Am J Hum Genet
Increased frequency of an allele raising apolipoprotein B (apoB) in a sample enriched for familial combined hyperlipidemia (FCH)
Am J Hum Genet
Cited by (39)
Nutrition interventions for youth with dyslipidemia: a National Lipid Association clinical perspective
2022, Journal of Clinical LipidologyCitation Excerpt :FCHL is one of the most common genetic causes of hyperlipidemia in the general population with an estimated prevalence of 0.5%−2.0%. Because of the peculiar variability of laboratory parameters and the frequent overlapping with the features of metabolic syndrome, FCHL is often not recognized nor appropriately treated in youth.37-38 Identifying FCHL during childhood can be difficult because of the lack of long-term data linking lipid values measured before age 12 to the expression of the disease in adulthood.
Hyperlipidemia in children
2006, Thrombosis ResearchAdolescents and genetic testing: What do they think about it?
2003, Journal of Adolescent HealthDrug therapy of hyperlipidemia
2003, Progress in Pediatric Cardiology
- *
Supported in part by grants HL-37435 and RR-00240 from the U.S. Public Health Service, National Institutes of Health, by a grant from the March of Dimes-Birth Defects Foundation (6-494), by a grant from the W. W. Smith Charitable Trust, and by a Nutrition Center Pilot Project grant supported by the Howard Heinz Endowment Fund.